FMS-like tyrosine kinase 3 (FLT3) mutations are common in patients with acute myeloid leukemia (AML), and is often associated with a poor prognosis. Despite the development of FLT3 inhibitors such as midostaurin, sorafenib, and qauizartinib, patients often progress on these therapies due to secondary mutations. Various strategies to improve patient outcomes such novel combinations with other agents including hypomethylating agents or venetoclax are currently under investigation.
In this podcast, Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX, and Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, have an insightful discussion on FLT3-mutated acute myeloid leukemia (AML) updates presented at the ASH 2021 annual meeting. They give an overview of the use of FLT3 inhibitors in combination with other agents, as well as trial data from the LACEWING trial (NCT02752035) of gilteritinib in combination with azacitidine in the frontline setting.
This interview took place at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, GA, 2021.
MPN highlights at ASH 2023: novel agents & ongoing clinical trials in ET, PV and MF
iwNHL 2023 Session V: Expanding the CAR platform in NHL
iwCLL 2023: The role of continuous BTKis, approaching Richter’s transformation & addressing the underrepresentation of elderly patients in trials
iwNHL 2023 Session IV: Novel therapies in NHL: BTK inhibitors, BTK degraders, and bispecific antibodies
Unmet needs in AL amyloidosis, novel treatment strategies being explored, and the role of CHIP
iwNHL 2023 Session III: Recent updates with the use of antibody-drug conjugates in NHL
MPN diagnosis & treatment: novel agents in PV, clinical guidance for the use of JAK inhibitors & the growing role of combination approaches
iwNHL 2023 Session II: The evolving treatment landscape in mantle cell lymphoma
iwNHL 2023 Session I: Updates on the biology and treatment of T-cell lymphoma
iwAL 2023 Session IV: transplantation and immunotherapies in AML: improving patient outcomes
Classifying frailty and approaching elderly patients with lymphoma
Updates on the diagnosis, risk stratification and treatment of lower-risk MDS
iwAL 2023 Session III: The relevance of TP53 mutation in AML
iwAL 2023 Session II: Novel treatments in AML: FLT3 inhibitors, combinations, and more
iwAL 2023 Session I: Clonal hematopoiesis in AML, early detection and potential therapeutics
Applications of MRD in multiple myeloma: using MRD to guide treatment decisions
Exploring and comparing the curative potential of CAR-T therapy & bispecific antibodies in R/R DLBCL
Pre-MDS states: improving prognosis, novel therapeutic approaches, and challenges with distinguishing these conditions
Accelerated-phase MPNs: mutational landscape, challenges, and novel treatment strategies being explored
Determining the optimal sequencing of bispecifics and CAR-T cells in multiple myeloma
Create your
podcast in
minutes
It is Free
Good Mood Revolution
Good Nurse Bad Nurse
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
The Peter Attia Drive
The Doctor’s Farmacy with Mark Hyman, M.D.